Skip to main content
. 2022 Aug 25;135(14):1716–1727. doi: 10.1097/CM9.0000000000002294

Figure 4.

Figure 4

Microbiota profile changes before and after therapy. (A) Shannon index analysis, ∗P < 0.05; (B) Simpson index analysis, ∗P < 0.05; (C) PLS-DA analysis on OTU level; (D) Microbial interaction network of significant changing genus before and after therapy (Dot color: different phylum level; dot diameter: RA; red line: positive correlation; green line: negative correlation; line color shade: correlation coefficient); (E,F) Significantly changed genus in IBSN and IBSP groups after rifaximin therapy; each dot represents the median RA for genus, ∗significant different genus for IBSN or IBSP in comparison with HC; #significant different genus for IBSP in comparison with HC and significant changes after rifaximin therapy. HC: Healthy control; IBS: irritable bowel syndrome; IBSP: breath test positive IBS patients; IBSPt: IBSP after rifaximin treatment; IBSN: breath test negative IBS patients; IBSNt: IBSN after rifaximin treatment; PLS-DA: Partial least squares discriminant analysis; RA: Relative abundance.